--- title: "TriSalus Life Sciences (TLSI) news: offering" url: "https://aibio.space/companies/trisalus-life-sciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "TLSI offering news: TriSalus agrees to sell 5,500,000 shares at $4.00 in $22.0 million private placement. TriSalus Life Sciences, Inc." --- TLSI TriSalus Life Sciences, Inc. NASDAQ · United States # TriSalus Life Sciences (TLSI) news TLSI offering news Mergers · 2025-04-30 ## [TriSalus agrees to sell 5,500,000 shares at $4.00 in $22.0 million private placement](https://aibio.space/news/trisalus-agrees-sell-5-500-000-shares-4-00-22-0-million-private/) TriSalus agreed to sell 5,500,000 shares at $4.00 in a private placement of about $22.0 million. The same deal ties it to an exchange offer for its Series A preferred stock, and the filing says the preferred terms would change. ## Latest TriSalus Life Sciences news 1. 2025-03-28 Distress [TriSalus Life Sciences files NT 10-K, citing errors and material weaknesses](https://aibio.space/news/trisalus-life-sciences-files-nt-10-k-citing-errors-material-weaknesses/) TriSalus says it cannot file its 2024 annual report on time after finding errors in stock-based compensation and clinical trial expenses. It expects to file by the fifteenth calendar day after the due date. Preliminary 2024 revenue was $29.4 million. 2. 2025-03-28 Distress [TriSalus Life Sciences delays 10-K after finding errors and material weaknesses](https://aibio.space/news/trisalus-life-sciences-delays-10-k-after-finding-errors-material/) The company found errors in the timing of stock-based compensation and clinical trial expenses. It expects to file its annual report within fifteen calendar days of the due date. 3. 2025-02-19 Financings [TriSalus Life Sciences receives $10 million second loan tranche, issues warrants for 91,263 shares](https://aibio.space/news/trisalus-life-sciences-receives-10-million-second-loan-tranche-issues/) The Second Tranche loan matures on April 30, 2029. Warrants issued to the initial lender and its affiliate carry an exercise price of $5.4787 and a term of 7 years. ## TriSalus Life Sciences at a glance - **Ticker**: TLSI - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $46.3 million ### Related companies - [10x Genomics](https://aibio.space/companies/10x-genomics/) NASDAQ: TXG - [CDT Equity](https://aibio.space/companies/cdt-equity/) NASDAQ: CDT - [Scholar Rock Holding](https://aibio.space/companies/scholar-rock/) NASDAQ: SRRK - [BioCryst Pharmaceuticals](https://aibio.space/companies/biocryst-pharmaceuticals/) NASDAQ: BCRX - [BioAtla](https://aibio.space/companies/bioatla/) OTC: BCAB - [Opus Genetics](https://aibio.space/companies/opus-genetics/) NASDAQ: IRD - [Enovis CORP](https://aibio.space/companies/enovis/) NYSE: ENOV - [Quanterix](https://aibio.space/companies/quanterix/) NASDAQ: QTRX ### Also on NASDAQ - [Corbus Pharmaceuticals Holdings](https://aibio.space/companies/corbus-pharmaceuticals/) CRBP - [Aquestive Therapeutics](https://aibio.space/companies/aquestive-therapeutics/) AQST - [Atea Pharmaceuticals](https://aibio.space/companies/atea-pharmaceuticals/) AVIR - [Evolus](https://aibio.space/companies/evolus/) EOLS - [Talphera](https://aibio.space/companies/talphera/) TLPH - [Gossamer Bio](https://aibio.space/companies/gossamer-bio/) GOSS ## What TriSalus Life Sciences does TriSalus Life Sciences is an oncology focused medical technology business that aims to improve outcomes for patients with solid tumors by combining its delivery technology with standard-of-care therapies and with its investigational immunotherapy, nelitolimod. Its Pressure-Enabled Drug Delivery (PEDD) method modulates pressure and flow within blood vessels to improve intravascular drug delivery into tumors. The on-market TriNav Infusion System, a 510(k) cleared device using PEDD, is used mainly for transarterial radioembolization and chemoembolization in primary liver cancer and liver metastases. TriSalus is also generating clinical data in thyroid, uterine artery and genicular artery embolization. Its Pancreatic Retrograde Venous Infusion device is also 510(k) cleared and is designed for pancreatic tumors, but it has not yet been commercialized. Nelitolimod, a class C Toll-like receptor 9 agonist, is being studied to reprogram immune cells in the liver and pancreas, and the company has completed Phase I and Phase Ib trials. It may seek a partner to advance nelitolimod into Phase II trials. | Product or program | What it is | Stage | |---|---|---| | TriNav Infusion System | Interventional radiology device using PEDD technology for liver tumor procedures | on-market, 510(k) cleared | | Pancreatic Retrograde Venous Infusion (PRVI) device | Device for infusions into pancreatic tumors through the venous vasculature | 510(k) cleared, not yet commercialized | | Nelitolimod | Investigational class C Toll-like receptor 9 agonist for liver and pancreas tumors | Phase I and Phase Ib completed | | PEDD technology | Pressure-Enabled Drug Delivery method for intravascular delivery into solid tumors | | Summarised from the company's [10-K filed Mar 5, 2026](https://www.sec.gov/Archives/edgar/data/1826667/000162828026015163/tlsi-20251231.htm). ## TriSalus Life Sciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$45.2 million](https://www.sec.gov/Archives/edgar/data/1826667/000162828026015163/) | [$29.4 million](https://www.sec.gov/Archives/edgar/data/1826667/000162828026015163/) | | Research and development | [$15.0 million](https://www.sec.gov/Archives/edgar/data/1826667/000162828026015163/) | [$17.7 million](https://www.sec.gov/Archives/edgar/data/1826667/000162828026015163/) | | Net income (loss) | [-$39.2 million](https://www.sec.gov/Archives/edgar/data/1826667/000162828026015163/) | [-$30.0 million](https://www.sec.gov/Archives/edgar/data/1826667/000162828026015163/) | | Cash from operations | [-$18.0 million](https://www.sec.gov/Archives/edgar/data/1826667/000162828026015163/) | [-$40.8 million](https://www.sec.gov/Archives/edgar/data/1826667/000162828026015163/) | | Cash and equivalents | [$20.4 million](https://www.sec.gov/Archives/edgar/data/1826667/000162828026054275/) | [$8.5 million](https://www.sec.gov/Archives/edgar/data/1826667/000162828026015163/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $46.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about TriSalus Life Sciences Has TriSalus Life Sciences raised money recently? Our latest story on this, dated Apr 30, 2025: "TriSalus agrees to sell 5,500,000 shares at $4.00 in $22.0 million private placement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/trisalus-agrees-sell-5-500-000-shares-4-00-22-0-million-private/). What is the ticker symbol of TriSalus Life Sciences? TriSalus Life Sciences, Inc. trades under the ticker TLSI on NASDAQ. Where is TriSalus Life Sciences listed? TriSalus Life Sciences, Inc. is listed on NASDAQ. What is the SEC CIK of TriSalus Life Sciences? The SEC Central Index Key (CIK) for TriSalus Life Sciences, Inc. is 1826667. Its filings are on SEC EDGAR. How many shares does TriSalus Life Sciences have outstanding? 61,574,600 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is TriSalus Life Sciences listed under? Our directory records TriSalus Life Sciences, Inc. under United States. What does TriSalus Life Sciences do? Our directory classifies TriSalus Life Sciences, Inc. as: Drug / device combination. This is a directory classification, not a description of the pipeline. What is the ISIN of TriSalus Life Sciences? The ISIN recorded for TriSalus Life Sciences, Inc. is US89680M1018. Does aibio.space cover TriSalus Life Sciences? aibio.space lists TriSalus Life Sciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is TriSalus Life Sciences incorporated? SEC records list its state or country of incorporation as DE. What does TriSalus Life Sciences develop? TriSalus Life Sciences is an oncology focused medical technology business that aims to improve outcomes for patients with solid tumors by combining its delivery technology with standard-of-care therapies and with its investigational immunotherapy, nelitolimod. Its Pressure-Enabled Drug Delivery (PEDD) method modulates pressure and flow within blood vessels to improve intravascular drug delivery into tumors. What is TriNav Infusion System from TriSalus Life Sciences? TriNav Infusion System: Interventional radiology device using PEDD technology for liver tumor procedures Stage: on-market, 510(k) cleared. What is Pancreatic Retrograde Venous Infusion (PRVI) device from TriSalus Life Sciences? Pancreatic Retrograde Venous Infusion (PRVI) device: Device for infusions into pancreatic tumors through the venous vasculature Stage: 510(k) cleared, not yet commercialized. What was TriSalus Life Sciences's revenue last year? $45.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is TriSalus Life Sciences profitable? TriSalus Life Sciences, Inc. reported a net loss of $39.2 million for the fiscal year ended Dec 31, 2025, and used $18.0 million of cash in operations, per its annual report to the SEC. ## Investor discussion: TriSalus Life Sciences Members talk about TriSalus Life Sciences (TLSI). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at TriSalus Life Sciences, newest first. Each line links the filing it comes from. 1. 2026-02-19 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1826667/000149315226007465/form424b5.htm) 2. 2025-06-23 Financings Offered to buy back its own securities. SEC Form SC TO-I. [Source](https://www.sec.gov/Archives/edgar/data/1826667/000164117225016156/formscto-i.htm) 3. 2025-04-30 Mergers Filed documents for a merger or acquisition. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1826667/000110465925041863/tm2513482d1_8k.htm) 4. 2025-03-28 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1826667/000182666725000027/trisaluslifesciencesntxq42.htm) 5. 2025-02-19 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 2.03,3.02). [Source](https://www.sec.gov/Archives/edgar/data/1826667/000182666725000018/tlsi-20250218.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:TLSI on TradingView](https://www.tradingview.com/symbols/NASDAQ-TLSI/). ## SEC filings and registration - **SEC name**: TriSalus Life Sciences, Inc. - **CIK**: 1826667 - **Industry (SIC)**: Surgical & Medical Instruments & Apparatus (3841) - **US tickers**: TLSI (Nasdaq), TLSIW (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 6272 WEST 91ST AVENUE, WESTMINSTER, CO, 80031 - **Phone**: 415 336 8917 - **Shares outstanding**: 61,574,600 as of 2026-08-04 (10-Q filed 2026-08-06) - **Former names**: MedTech Acquisition Corp; MedTech Acquisition Corporation ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1826667/000162828026063031/tlsi-20260922.htm) filed 2026-09-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/1826667/000162828026054275/tlsi-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1826667/000162828026054264/tlsi-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1826667/000162828026035068/tlsi-20260514.htm) filed 2026-05-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1826667/000162828026034100/tlsi-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1826667/000162828026034082/tlsi-20260512.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1826667/000162828026028425/tlsi-20260424.htm) filed 2026-04-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1826667/000162828026023991/tlsi-20260401.htm) filed 2026-04-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001826667), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details TriSalus Life Sciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TLSI, recorded under United States. The directory classifies it as Drug / device combination. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: TriSalus Life Sciences, Inc. - **Ticker**: TLSI - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Drug / device combination - **ISIN**: US89680M1018 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-TLSI/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/trisalus-life-sciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "TriSalus Life Sciences (TLSI) news: offering", 2026-10-31, https://aibio.space/companies/trisalus-life-sciences/